Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896863 | 0.84 | NPC1 (0.69) | MAP4K4NPC1RAB9AHPGDGAA | |
| SCHEMBL17896328 | 0.82 | MAP4K4 (0.52) | MAP4K4NPC1RAB9AHPGDCYP3A4 | |
| SCHEMBL6409278 | 0.73 | POLB (0.63) | NPC1RAB9ACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12569855 | 0.73 | FADS1 (0.55) | RAB9AHPGDGAALMNASMN1; SMN2 | |
| SCHEMBL21349057 | 0.72 | KDM4E (0.51) | HPGDTDP1RXFP1LMNAALDH1A1 | |
| SCHEMBL13547747 | 0.72 | FADS1 (0.54) | RAB9AHPGDGAALMNASMN1; SMN2 | |
| SCHEMBL4002308 | 0.72 | SMN1; SMN2 (0.55) | NPC1RAB9AHPGDLMNASMN1; SMN2 | |
| SCHEMBL11795655 | 0.72 | SMN1; SMN2 (0.63) | NPC1RAB9AHPGDCYP2C9CYP2C19 | |
| SCHEMBL967250 | 0.72 | FADS1 (0.57) | NPC1RAB9AHPGDLMNAALDH1A1 | |
| SCHEMBL19540323 | 0.71 | LMNA (0.75) | HPGDGAARXFP1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | MAP4K4 700/4885NPC1 2128/4885RAB9A 1222/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885NPC1 3072/4885RAB9A 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.